NICE recommends Celgene pancreatic cancer drug

08:57 EDT 4 Aug 2017 | pharmaphorum

NICE has recommended regular NHS funding for Celgene’s advanced pancreatic cancer drug Abraxane in certain patients, after the manufacturer submitted evidence and offered a price cut, reversing a negative decision from 2015. Campaigners had been...

Original Article: NICE recommends Celgene pancreatic cancer drug


More From BioPortfolio on "NICE recommends Celgene pancreatic cancer drug"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...